STING agonists increased type I IFN expression to promote the maturation of DCs and thus effectively enabled the cross‐presentation of tumor antigens to activate T cells, increase TNBC immunogenicity, and recruit CD8+ T cells and NK cells into the tumor site to transform cold tumors into hot tumors. The gene discussed is STING1; the disease is neoplasm.